Israel
· Delayed Price · Currency is ILS · Price in ILALineage Cell Therapeutics Statistics
Total Valuation
Lineage Cell Therapeutics has a market cap or net worth of ILS 591.68 million. The enterprise value is 452.54 million.
| Market Cap | 591.68M |
| Enterprise Value | 452.54M |
Important Dates
The next estimated earnings date is Thursday, November 7, 2024.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.05% |
| Shares Change (QoQ) | +3.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 146.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.97 |
| EV / Sales | 19.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.38 |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.64 |
| Quick Ratio | 2.54 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.13 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -35.04% and return on invested capital (ROIC) is -19.09%.
| Return on Equity (ROE) | -35.04% |
| Return on Assets (ROA) | -12.86% |
| Return on Capital (ROIC) | -19.09% |
| Revenue Per Employee | 323,485 |
| Profits Per Employee | -1.26M |
| Employee Count | 75 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6,394.05% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +6,394.05% |
| 50-Day Moving Average | 337.11 |
| 200-Day Moving Average | 354.08 |
| Relative Strength Index (RSI) | 41.75 |
| Average Volume (20 Days) | 6,534 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 32.03 |
Income Statement
In the last 12 months, Lineage Cell Therapeutics had revenue of ILS 23.29 million and -91.07 million in losses. Loss per share was -0.50.
| Revenue | 23.29M |
| Gross Profit | 29.36M |
| Operating Income | -83.08M |
| Pretax Income | -91.13M |
| Net Income | -91.07M |
| EBITDA | -80.56M |
| EBIT | -83.08M |
| Loss Per Share | -0.50 |
Balance Sheet
The company has 144.94 million in cash and 11.11 million in debt, giving a net cash position of 133.83 million.
| Cash & Cash Equivalents | 144.94M |
| Total Debt | 11.11M |
| Net Cash | 133.83M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 251.79M |
| Book Value Per Share | 1.36 |
| Working Capital | 94.56M |
Cash Flow
In the last 12 months, operating cash flow was -82.89 million and capital expenditures -1.20 million, giving a free cash flow of -84.09 million.
| Operating Cash Flow | -82.89M |
| Capital Expenditures | -1.20M |
| Free Cash Flow | -84.09M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 126.08% |
| Operating Margin | -356.69% |
| Pretax Margin | -391.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -361.02% |
Dividends & Yields
Lineage Cell Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.05% |
| Shareholder Yield | -6.05% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Lineage Cell Therapeutics has an Altman Z-Score of -2.23. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.23 |
| Piotroski F-Score | n/a |